Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132806) titled 'Efficacy and Safety of Ivosiditumab Combined with Chemotherapy as Neoadjuvant Therapy in Patients with Resectable SMARCA4deficient NonSmall Cell Lung Cancer: A SingleArm, SingleCenter, Phase II Clinical Study' on Sept. 18.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
Condition:
resectable SMARCA4deficient stage IIIIIB nonsmall cell lung cancer (NSCLC)
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-10-01
Target Sample Size: Ivonescimab plus...